TAK Overview
Upcoming Projects (TAK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (TAK)
-
Speaking with a third physician about EOHILIA (budesonide oral suspension) for patients with Eosinophilic Esophagitis (EoE).
Ticker: TAK
Executed On: Oct 08, 2024 at 08:00 AM EDT -
Speaking with a second physician about EOHILIA (budesonide oral suspension) for patients with Eosinophilic Esophagitis (EoE).
Ticker: TAK
Executed On: Sep 20, 2024 at 10:00 AM EDT -
Speaking with a gastroenterologist about EOHILIA (budesonide oral suspension) for patients with Eosinophilic Esophagitis (EoE).
Ticker: TAK
Executed On: Sep 17, 2024 at 11:00 AM EDT -
A Third Opinion: Discussing the recent data from Takeda's phase 2b trial of TAK-861 as a treatment for patients with narcolepsy.
Tickers: TAK, JAZZ
Executed On: Aug 01, 2024 at 03:00 PM EDT -
A Second Opinion: Discussing the recent data from Takeda's phase 2b trial of TAK-861 as a treatment for patients with narcolepsy.
Tickers: TAK, JAZZ
Executed On: Jul 26, 2024 at 12:00 PM EDT -
A Second Look: Discussing the FDA expanded label for ENTYVIO® (vedolizumab) for subcutaneous (SC) administration maintenance therapy in adults with moderately to severely active Crohn’s Disease.
Ticker: TAK
Executed On: Jun 25, 2024 at 04:30 PM EDT -
A Third Look: Discussing the FDA expanded label for ENTYVIO® (vedolizumab) for subcutaneous (SC) administration maintenance therapy in adults with moderately to severely active Crohn’s Disease.
Ticker: TAK
Executed On: Jun 25, 2024 at 12:00 PM EDT -
Discussing the recent data from Takeda's phase 2b trial of TAK-861 as a treatment for patients with narcolepsy.
Tickers: TAK, JAZZ
Executed On: Jun 17, 2024 at 04:00 PM EDT -
Discussing the FDA expanded label for ENTYVIO® (vedolizumab) for subcutaneous (SC) administration maintenance therapy in adults with moderately to severely active Crohn’s Disease.
Ticker: TAK
Executed On: May 21, 2024 at 02:00 PM EDT -
A Second Look: Discussing the recent FDA approval and potential of Takeda's FRUZAQLA (fruquintinib) in previously treated metastatic colorectal cancer patients
Ticker: TAK
Executed On: Feb 14, 2024 at 11:00 AM EST -
Discussing the recent FDA approval and potential of Takeda's FRUZAQLA (fruquintinib) in previously treated metastatic colorectal cancer patients
Ticker: TAK
Executed On: Jan 18, 2024 at 04:00 PM EST -
A Third Opinion: Discussing the results from the Phase 2b Study evaluating Takeda's TAK-279 for the treatment of active psoriatic arthritis
Ticker: TAK
Executed On: Oct 11, 2023 at 06:00 PM EDT -
A Second Opinion: Discussing the results from the Phase 2b Study evaluating Takeda's TAK-279 for the treatment of active psoriatic arthritis
Ticker: TAK
Executed On: Oct 04, 2023 at 01:00 PM EDT -
Discussing the results from the Phase 2b Study evaluating Takeda's TAK-279 for the treatment of active psoriatic arthritis
Ticker: TAK
Executed On: Sep 15, 2023 at 02:30 PM EDT -
A second look: Discussion of therapeutic options in NT1 (Narcolepsy Type 1) and Orexin agonists
Tickers: JAZZ, TAK, AVDL, HRMY
Executed On: Aug 10, 2023 at 01:30 PM EDT -
Discussion of therapeutic options in NT1 (Narcolepsy Type 1) and Orexin agonists
Tickers: TAK, JAZZ, AVDL, HRMY
Executed On: Aug 09, 2023 at 05:30 PM EDT -
A second opinion: Discussing the standard of care and the potential of ENTYVIO (vedolizumab) as a maintenance therapy given subcutaneously for ulcerative colitis.
Ticker: TAK
Executed On: Jun 01, 2023 at 03:15 PM EDT -
Discussing the standard of care and the potential of ENTYVIO (vedolizumab) as a maintenance therapy given subcutaneously for ulcerative colitis.
Ticker: TAK
Executed On: May 10, 2023 at 05:00 PM EDT -
A third discussion of the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 23, 2022 at 03:00 PM EDT -
A second discussion of the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 23, 2022 at 02:00 PM EDT -
Discussing the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 22, 2022 at 12:00 PM EDT -
A look at the potential of HYQVIA as maintenance therapy in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and it's positive topline results from the P3 ADVANCE-1 trial
Ticker: TAK
Executed On: Aug 23, 2022 at 05:30 PM EDT -
A final look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, IONS, TAK, CSLLY
Executed On: Jul 26, 2022 at 06:00 PM EDT -
A Third look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, IONS, TAK, CSLLY
Executed On: Jul 22, 2022 at 01:15 PM EDT -
A Second look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, IONS, TAK, CSLLY
Executed On: Jul 22, 2022 at 12:00 PM EDT -
A look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, TAK, IONS, CSLLY
Executed On: Jul 22, 2022 at 08:15 AM EDT
Upcoming & Overdue Catalysts (TAK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (TAK)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
